论文部分内容阅读
花粉症应用免疫疗法效果肯定,但有引发局部和全身反应的可能性,偶亦见有过敏休克者。聚合(polymerized)全豕草花粉抗原为将豕草花粉抗原制成高分子量的聚合体,此聚合体抗原与组织中肥大细胞的结合能力有所降低,但仍能保持其刺激封闭抗体产生的作用。由于其变应原性减低,允许以较大剂量开始并以之为维持量继续治疗,使注射次数减少,即刻型局部和全身反应率减低。本文报道美国四个城市1979年应用聚合全豕草花粉抗原治疗80例花粉症患者(每个城市20例)的效果。每一患者具有1978年(治疗前)和1979年(治疗后)两年的症状记分,另有未进行治疗的20例患者的1979年症状记分作为对照。同时对四个城市两年中的豕草花粉进行计数。治疗开始于1979年3月,开始剂量为100PNU(蛋白氮单位),每周注射一次,逐渐增加剂量,共15周。除1例(总量25,000PNU)外总量皆达50,000PNU。
Application of hay fever effect of immunotherapy affirmation, but there is the possibility of triggering local and systemic reactions, even see also have allergic shock. Polymerization (polymerized) whole hay fever pollen antigen The hay fever pollen antigen made of high molecular weight polymer, the polymer antigen and tissue mast cells decreased binding capacity, but still able to maintain its role in stimulating the blocking antibody . Due to its reduced allergenicity, allowing larger doses to begin and continue as the maintenance dose, reducing the number of injections and immediate local and systemic response rates. This article reports the effects of treating 80 cases of hay fever (20 cases in each city) using polymerised hay fever pollen antigen in four U.S. cities in 1979. Each patient had a symptom score of two years prior to treatment (pre-treatment) and 1979 (post-treatment), and another 1979 patients with symptom scores of 20 patients who were untreated were used as controls. At the same time, the pollen of hay fever in two cities in four cities was counted. Treatment began in March 1979 with a starting dose of 100PNU (protein nitrogen units) and was given weekly and the dose was gradually increased for a total of 15 weeks. Excluding one case (total 25,000 PNU), the total amount reached 50,000 PNU.